Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Recurrent Extensive Stage SCLC
NCT03670056Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Dec 2018
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in small cell lung cancer (SCLC), sponsored by Yale University. Started Dec 2018; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03670056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670056.